β-Catenin and FAT1 Protein Expressions for Prediction of Survival Outcome in Type I Endometrial Cancer
Kanet Kanjanapradit MD¹, Poowadon Wetwittayakhlung MD¹, Athithan Rattanaburi MD²
Affiliation : ¹ Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand ² Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Background : Endometrial cancer (EC) is the second most common female genital tract malignancy and has adverse outcome in the advanced
stage. A prognostic marker is needed for marking an accurate prognostic.
Objective : To evaluate expression and clinical outcome of CTNNB1 (β-catenin) and FAT atypical cadherin 1 (FAT1), by using immunohistochemical staining in EC type I. Materials and Methods : Seventy-two EC type I cases were selected from Songklanagarind Hospital with clinical data collection. All cases were evaluated by immunohistochemistry using antibodies against β-catenin and FAT1.
Results : All cases of EC type I were β-catenin positive and FAT1 negative. Moderate and strong intensity (2+ and 3+) β-catenin cytoplasmic staining showed statistically significant association with low grade EC, and low risk of recurrence disease or metastasis (p<0.05). β-catenin nuclear staining was present in 19 of 28 cases (68%) of EC grade 1 and associated with low grade EC. β-catenin and FAT1 expression were not associated with 5-year overall survival in both univariate and multivariate analyses.
Conclusion : β-catenin cytoplasmic staining may be associated with low grade EC, and helpful to predict recurrent risk. However, FAT1 and β-catenin expressions have no statically significant correlation with 5-year overall survival and cannot be used to determine the prognosis in type I EC patients.
Received 21 September 2020 | Revised 16 February 2021 | Accepted 22 February 2021
doi.org/10.35755/jmedassocthai.2021.05.12037
Keywords : β-catenin, FAT1, Immunohistochemistry, Metastasis, Recurrence, Survival outcome, Type I endometrial cancer
